NCT02454179View on ClinicalTrials.gov

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

78

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

July 31, 2018

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

pembrolizumab

DRUG

Acalabrutinib

Trial Locations (1)

Unknown

Oregon Health and Science University, Portland

Sponsors

Lead Sponsor

Acerta Pharma BV

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY